Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:PHVS NASDAQ:PRAX NASDAQ:YMAB NYSE:ZYME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumePHVSPharvaris$23.00+0.0%$17.49$11.51▼$26.33$1.20B-2.8273,164 shs32,315 shsPRAXPraxis Precision Medicines$53.63+3.4%$42.42$26.70▼$91.83$1.09B2.6368,983 shs338,213 shsYMABY-mAbs Therapeutics$4.35+3.1%$4.49$3.55▼$16.11$196.99M0.51294,224 shs181,704 shsZYMEZymeworks$13.52+5.0%$12.30$9.03▼$17.70$942.11M1.19578,080 shs537,710 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformancePHVSPharvaris-3.40%+27.86%+37.66%+67.57%+28.72%PRAXPraxis Precision Medicines-3.19%+10.97%+17.13%+73.95%+1.79%YMABY-mAbs Therapeutics-3.21%+0.24%-10.40%-7.05%-67.49%ZYMEZymeworks-3.52%-0.54%+1.66%+14.49%+25.41%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationPHVSPharvaris1.5351 of 5 stars3.51.00.00.01.90.00.0PRAXPraxis Precision Medicines2.2493 of 5 stars4.41.00.00.01.61.70.0YMABY-mAbs Therapeutics4.1493 of 5 stars4.45.00.00.03.32.50.6ZYMEZymeworks3.0361 of 5 stars3.54.00.00.02.43.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PricePHVSPharvaris 3.00Buy$36.2057.39% UpsidePRAXPraxis Precision Medicines 2.78Moderate Buy$94.1175.48% UpsideYMABY-mAbs Therapeutics 2.82Moderate Buy$15.60258.62% UpsideZYMEZymeworks 2.90Moderate Buy$21.0055.33% UpsideCurrent Analyst Ratings BreakdownLatest YMAB, PRAX, PHVS, and ZYME Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/8/2025PRAXPraxis Precision MedicinesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$97.00 ➝ $115.007/3/2025ZYMEZymeworksHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$13.006/12/2025PRAXPraxis Precision MedicinesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.006/11/2025PHVSPharvarisGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$32.006/5/2025PHVSPharvarisWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$27.006/2/2025PRAXPraxis Precision MedicinesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperform$97.005/29/2025YMABY-mAbs TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$20.00 ➝ $15.005/28/2025YMABY-mAbs TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$21.00 ➝ $18.005/20/2025ZYMEZymeworksTD SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy5/20/2025ZYMEZymeworksTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy5/19/2025YMABY-mAbs TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $11.00(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookPHVSPharvarisN/AN/AN/AN/A$5.54 per shareN/APRAXPraxis Precision Medicines$8.55M127.77N/AN/A$23.90 per share2.24YMABY-mAbs Therapeutics$88.66M2.22N/AN/A$2.05 per share2.12ZYMEZymeworks$93.38M10.09N/AN/A$6.63 per share2.04Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DatePHVSPharvaris-$145.24M-$3.01N/AN/AN/AN/A-54.02%-50.36%8/13/2025 (Estimated)PRAXPraxis Precision Medicines-$182.82M-$10.72N/AN/AN/A-2,137.48%-50.42%-46.74%8/12/2025 (Estimated)YMABY-mAbs Therapeutics-$29.67M-$0.64N/AN/AN/A-31.84%-30.59%-22.70%8/11/2025 (Estimated)ZYMEZymeworks-$118.67M-$1.49N/AN/AN/A-182.75%-23.00%-18.04%7/30/2025 (Estimated)Latest YMAB, PRAX, PHVS, and ZYME EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q1 2025PHVSPharvaris-$0.87N/AN/AN/AN/AN/A8/12/2025Q2 2025PRAXPraxis Precision Medicines-$3.40N/AN/AN/A$0.16 millionN/A8/11/2025Q2 2025YMABY-mAbs Therapeutics-$0.27N/AN/AN/A$18.40 millionN/A8/7/2025N/AZYMEZymeworks-$0.52N/AN/AN/A$17.18 millionN/A5/13/2025Q1 2025PHVSPharvaris-$0.80-$0.89-$0.09-$0.89N/AN/A5/13/2025Q1 2025YMABY-mAbs Therapeutics-$0.22-$0.12+$0.10-$0.12$19.97 million$20.90 million5/8/2025N/AZYMEZymeworks-$0.45-$0.30+$0.15N/A$20.65 million$27.11 million5/2/2025Q1 2025PRAXPraxis Precision Medicines-$3.20-$3.29-$0.09-$3.29$0.20 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthPHVSPharvarisN/AN/AN/AN/AN/APRAXPraxis Precision MedicinesN/AN/AN/AN/AN/AYMABY-mAbs TherapeuticsN/AN/AN/AN/AN/AZYMEZymeworksN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioPHVSPharvarisN/A11.1011.10PRAXPraxis Precision MedicinesN/A8.448.44YMABY-mAbs TherapeuticsN/A4.774.35ZYMEZymeworksN/A4.104.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipPHVSPharvarisN/APRAXPraxis Precision Medicines67.84%YMABY-mAbs Therapeutics70.85%ZYMEZymeworks92.89%Insider OwnershipCompanyInsider OwnershipPHVSPharvarisN/APRAXPraxis Precision Medicines2.70%YMABY-mAbs Therapeutics19.70%ZYMEZymeworks1.92%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionablePHVSPharvaris3052.29 millionN/ANot OptionablePRAXPraxis Precision Medicines11020.37 million19.82 millionOptionableYMABY-mAbs Therapeutics15045.28 million36.36 millionOptionableZYMEZymeworks46069.68 million67.56 millionOptionableYMAB, PRAX, PHVS, and ZYME HeadlinesRecent News About These CompaniesZymeworks Inc. (NYSE:ZYME) Receives Consensus Rating of "Moderate Buy" from BrokeragesJuly 16 at 2:48 AM | marketbeat.comZYME | Zymeworks Inc. Annual Cash Flow Statement | MarketWatchJuly 11, 2025 | marketwatch.comBispecific Antibody Clinical Trial Pipeline Gains Momentum: 180+ Companies Lead the Charge in Pioneering New Treatments | DelveInsightJuly 9, 2025 | finance.yahoo.comZymeworks (NYSE:ZYME) Given "Neutral" Rating at HC WainwrightJuly 3, 2025 | marketbeat.comZymeworks Amends Warrant Agreement with EcoR1 CapitalJune 27, 2025 | tipranks.comZYME - Zymeworks Inc Registered Shs Dividends - MorningstarJune 27, 2025 | morningstar.comMCompanies Like Zymeworks (NASDAQ:ZYME) Are In A Position To Invest In GrowthJune 25, 2025 | finance.yahoo.comZymeworks Inc. (NYSE:ZYME) Given Average Recommendation of "Moderate Buy" by BrokeragesJune 21, 2025 | marketbeat.comAll You Need to Know About Zymeworks (ZYME) Rating Upgrade to BuyJune 20, 2025 | zacks.comRhumbline Advisers Has $985,000 Stock Position in Zymeworks Inc. (NYSE:ZYME)June 20, 2025 | marketbeat.comDuncan Williams Asset Management LLC Buys Shares of 22,095 Zymeworks Inc. (NYSE:ZYME)June 19, 2025 | marketbeat.comZymeworks Inc (NASDAQ:ZYME) Valuation Biotech Sector Trends S&P 500June 18, 2025 | kalkinemedia.comKSG Americas Securities LLC Raises Position in Zymeworks Inc. (NYSE:ZYME)June 17, 2025 | marketbeat.comZymeworks: Early-Stage Biotech Feel Despite Zanidatamab Advancements (Downgrade)June 12, 2025 | seekingalpha.comWall Street Analysts See a 76.74% Upside in Zymeworks (ZYME): Can the Stock Really Move This High?June 4, 2025 | zacks.comZymeworks’ zanidatamab gains approval in China for biliary tract cancerJune 2, 2025 | msn.comRoche’s 96-week data for multiple sclerosis drug; ZymeWorks claims $20M milestoneMay 30, 2025 | endpts.comEChina's NMPA Approves Zymeworks' Ziihera for HER2-High Biliary Tract CancerMay 30, 2025 | precisionmedicineonline.comPZymeworks’ zanidatamab approved in ChinaMay 30, 2025 | thepharmaletter.comTZymeworks’ Drug Gets Conditional Approval For Biliary Tract Cancer Treatment In China: Retail Sentiment Refuses To BudgeMay 30, 2025 | msn.comZymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract CancerMay 30, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeYMAB, PRAX, PHVS, and ZYME Company DescriptionsPharvaris NASDAQ:PHVS$23.00 +0.01 (+0.04%) Closing price 04:00 PM EasternExtended Trading$22.94 -0.07 (-0.28%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.Praxis Precision Medicines NASDAQ:PRAX$53.63 +1.74 (+3.35%) Closing price 04:00 PM EasternExtended Trading$51.94 -1.69 (-3.15%) As of 06:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.Y-mAbs Therapeutics NASDAQ:YMAB$4.35 +0.13 (+3.08%) Closing price 04:00 PM EasternExtended Trading$4.33 -0.02 (-0.55%) As of 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.Zymeworks NYSE:ZYME$13.52 +0.64 (+4.97%) Closing price 04:00 PM EasternExtended Trading$13.51 -0.01 (-0.07%) As of 04:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD Just Triggered a Signal Traders Can’t Ignore JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now This ASML Dip Could Be Gone Before You Know It—Don’t Miss Out Rocket Lab Gets New Street-High Price Target from Citi Super Micro Stock May Benefit as Cooling Demand Takes Off Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings Salesforce Stock Set for 30% Upside to Reach New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
